Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Managing expectations in the long-term treatment of Alzheimer's disease
Autore:
Gauthier, S;
Indirizzi:
McGillnada Studies Aging, Alzheimers Dis Study Unit, Verdun, PQ H4H 1R3, Ca McGill Ctr Studies Aging Verdun PQ Canada H4H 1R3 Verdun, PQ H4H 1R3, Ca
Titolo Testata:
GERONTOLOGY
, volume: 45, anno: 1999, supplemento:, 1
pagine: 33 - 38
SICI:
0304-324X(1999)45:<33:MEITLT>2.0.ZU;2-N
Fonte:
ISI
Lingua:
ENG
Soggetto:
NURSING-HOME PLACEMENT; SPOUSE-CAREGIVERS; CONTROLLED TRIAL; PREVALENCE; DIAGNOSIS; DEMENTIA; INTERVENTION; MANAGEMENT; POPULATION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
35
Recensione:
Indirizzi per estratti:
Indirizzo: Gauthier, S McGillrdun,Studies Aging, Alzheimers Dis Study Unit, 6825 BoulLa Salle, Ve McGill Ctr Studies Aging 6825 Boul La Salle Verdun PQ Canada H4H 1R3
Citazione:
S. Gauthier, "Managing expectations in the long-term treatment of Alzheimer's disease", GERONTOLOGY, 45, 1999, pp. 33-38

Abstract

Alzheimer's disease (AD) is rare before the sixth decade of life, but becomes more prevalent with age. As the elderly proportion of the population isincreasing, the prevalence of AD is predicted to expand. Although there isno 'cure' for AD, focused therapeutic interventions may be initiated at a treatable stage of the disease if a diagnosis of AD is established early. For example, cholinesterase inhibitor therapy that is targeted towards the mild to moderate disease stages might be initiated. Results from an open-label study suggest that the benefits of donepezil are maintained for at least2 years. The disease has major implications for the patients' caregivers, who experience a burden that increases over time and which may result in a significant loss of income. Both patients and caregivers can benefit from pharmacological and nonpharmacological therapeutic strategies. For example, caregiver support programmes may ease the burden of AD and result in a greater potential for the successful treatment of patients with AD, and may delay or even prevent the early institutionalization of the patient. Currently, therefore, pharmacological treatments, supported by nonpharmacological strategies, are the mainstay of therapy for AD patients and their caregivers. In the future, studies are required to clarify whether other compounds, including oestrogen replacement therapy, antioxidants and anti-inflammatory, may slow or delay disease onset, or halt disease progression.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/04/20 alle ore 22:11:48